eligibility_summary
Eligible: CD30+ Hodgkin, aggressive NHL, or ALK+/- peripheral T-cell lymphoma, age 12-75, bilirubin <=2x ULN (<=3x if Gilbert), AST <=3x, eGFR >70, O2 sat >90%, no significant arrhythmia, KPS/Lansky >60%, available allogeneic T cells with >=15% CD30CAR, recovered from prior toxicities, contraception, consent. Exclude: investigational/vaccine <=6 wks, CD30 Ab <=4 wks, murine allergy, pregnant/lactating, airway-risk tumor, steroids >10 mg/d, active infection, NYHA III-IV.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Allogeneic CD30.CAR-EBVSTs—banked Epstein-Barr virus–specific T lymphocytes engineered with a CD30-directed chimeric antigen receptor (adoptive cellular immunotherapy, biological). Mechanism: CAR binding to CD30 on tumor cells triggers T-cell activation and cytotoxicity, native EBV-specific TCR enables recognition of EBV antigens in EBV+ tumors, potentially enhancing persistence/expansion and providing dual targeting. Lymphodepletion (cyclophosphamide + fludarabine, chemotherapy) is used to reduce host lymphocytes and improve engraftment. Targets: CD30-expressing malignant cells in classical Hodgkin lymphoma, aggressive NHL (incl. DLBCL), anaplastic large cell and other T/NK-cell lymphomas, EBV-positive tumor cells. Pathways: CAR/TCR signaling leading to tumor cell lysis, depletion of CD30+ cells.